tgDCC-E1A gene therapy - Targeted Genetics

Drug Profile

tgDCC-E1A gene therapy - Targeted Genetics

Alternative Names: E1A gene therapy; HER-2/neu inhibitor; LF 160519; RGG 0853

Latest Information Update: 14 Mar 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Targeted Genetics
  • Developer Targeted Genetics; Targeted Genetics Corporation
  • Class Antineoplastics; Gene therapies
  • Mechanism of Action ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Breast cancer; Head and neck cancer; Ovarian cancer

Most Recent Events

  • 14 Aug 2002 Suspended - Phase-I for Ovarian cancer in USA (Intratumoural)
  • 07 Aug 2002 Suspended - Phase-I for Ovarian cancer in Europe (Intratumoural)
  • 07 Aug 2002 Suspended - Phase-II for Head and neck cancer in USA (Intratumoural)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top